Our Services
Medical Information
Helpful Resources
Published on: 7/2/2026
GLP-1 receptor agonists rarely cause hypoglycemia on their own, but the risk increases significantly when combined with insulin, sulfonylureas, skipped meals, or intense exercise.
Key warning signs of low blood sugar include:
Prevention strategies:
Because hypoglycemia symptoms overlap with many other conditions—and because GLP-1 side effects can vary widely—it's worth understanding exactly what your body is signaling before your next appointment. Taking a free, instant, online symptom check can help you clarify your symptoms, identify potential causes, and confidently navigate your next steps with your healthcare provider.
Reviewed for medical accuracy: 07/02/2026
GLP-1 receptor agonists (often shortened to "GLP-1") are increasingly prescribed to help manage type 2 diabetes and support weight loss. They work by stimulating insulin release when blood sugar is high, slowing digestion, and reducing appetite. While these medications generally carry a low risk of hypoglycemia (low blood sugar) on their own, that risk can rise when you combine them with other treatments or skip meals. Understanding how to recognize low blood sugar symptoms, prevent dangerous lows, and act quickly can keep you safe and in control.
• GLP-1 drugs (exenatide, liraglutide, semaglutide, dulaglutide, etc.) enhance glucose-dependent insulin release.
• They slow gastric emptying, so carbohydrates enter the bloodstream more gradually.
• On their own, they rarely cause blood sugar to drop too low.
• Risk increases when used alongside:
– Insulin
– Sulfonylureas (e.g., glipizide, glyburide)
– Skipping or delaying meals
Knowing your total medication profile and meal plan is key to avoiding unexpected lows.
Certain factors can raise the chance of hypoglycemia when you're on GLP-1 therapy:
If any of these apply, consider more frequent monitoring and extra precautions.
Low blood sugar often develops rapidly. Early recognition allows for prompt treatment. Common GLP-1 and low blood sugar symptoms include:
Some people experience severe symptoms such as slurred speech, loss of coordination, seizures, or unconsciousness. If you feel "off" in any way, check your blood sugar without delay.
Maintain consistent meal and snack timing
Coordinate medications and meals
Monitor blood glucose regularly
Adjust for activity
Limit alcohol or pair it with food
Educate your circle
If you detect a low blood sugar (typically < 70 mg/dL), follow the "15-15 Rule":
For severe hypoglycemia (unable to swallow, seizures, unconscious), someone should administer a glucagon injection or nasal glucagon kit and call emergency services immediately.
Always discuss any serious or recurrent lows with your healthcare provider. Seek urgent care or call emergency services if you experience:
Concerned about your symptoms? Use Ubie's free AI-powered Hypoglycemia symptom checker to get personalized insights about your condition and understand when you should seek medical care.
Keeping blood sugar in your target range while on GLP-1 therapy is a team effort:
Your safety matters. If you have questions about hypoglycemia or your GLP-1 medication, please speak to your doctor or diabetes care team to tailor a plan that keeps you both safe and confident in managing your blood sugar.
(References)
* Nauck MA, Meier JJ. GLP-1 Receptor Agonists and the Risk of Hypoglycemia: An Update. Diabetes Ther. 2023 Apr;14(4):727-742. doi: 10.1007/s13300-023-01389-9. Epub 2023 Mar 23. PMID: 36959550; PMCID: PMC10058509.
* Nauck MA, Meier JJ. The differential effects of GLP-1 receptor agonists on hypoglycemia. Diabetes Obes Metab. 2021 May;23(5):1093-1107. doi: 10.1111/dom.14322. Epub 2021 Feb 21. PMID: 33580556.
* American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S191. doi: 10.2337/dc24-S009. PMID: 38169990.
* Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metab. 2018 Apr 3;27(4):746-757. doi: 10.1016/j.cmet.2018.03.001. PMID: 29614216.
* Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. PMID: 27295427.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.